{"transactions":[{"id":2334787,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":129140,"kind":"person","name":"Abrahmsen Lars B.","position":1,"cik":"0001789039","reported_name":"Abrahmsen Lars B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2022-03-14T21:01:04.000Z","date":"2022-03-10","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":100000,"derivative":{"exercise_price":1.82,"expiration_date":"2032-03-10","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-22-033389","document":"tm229119-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922033389/tm229119-1_4seq1.xml","form_type":"4"}},{"id":2334786,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":129140,"kind":"person","name":"Abrahmsen Lars B.","position":1,"cik":"0001789039","reported_name":"Abrahmsen Lars B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-03-14T21:01:04.000Z","date":"2022-03-10","kind":"grant","acquired":true,"shares":24700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 8,233 shares on March 10, 2023, (ii) 8,233 shares on March 10, 2024 and (iii) 8,234 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":43700,"source":{"system":"sec-edgar","filing":"0001104659-22-033389","document":"tm229119-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922033389/tm229119-1_4seq1.xml","form_type":"4"}},{"id":2547754,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":129140,"kind":"person","name":"Abrahmsen Lars B.","position":1,"cik":"0001789039","reported_name":"Abrahmsen Lars B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2021-10-05T21:01:43.000Z","date":"2021-10-01","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on September 14, 2016 and is fully exercisable."}],"balance_after":30587,"derivative":{"exercise_price":0.92,"expiration_date":"2026-09-14","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-21-123186","document":"tm2129205-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465921123186/tm2129205-2_4seq1.xml","form_type":"4"}},{"id":2547753,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":129140,"kind":"person","name":"Abrahmsen Lars B.","position":1,"cik":"0001789039","reported_name":"Abrahmsen Lars B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:01:43.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":50000,"price":4.89,"value":244500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.79 to $5.05 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":19000,"source":{"system":"sec-edgar","filing":"0001104659-21-123186","document":"tm2129205-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465921123186/tm2129205-2_4seq1.xml","form_type":"4"}},{"id":2547752,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":129140,"kind":"person","name":"Abrahmsen Lars B.","position":1,"cik":"0001789039","reported_name":"Abrahmsen Lars B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:01:43.000Z","date":"2021-10-01","kind":"exercise","acquired":true,"shares":50000,"price":0.92,"value":46000.0,"ownership":{"direct":true},"balance_after":69000,"source":{"system":"sec-edgar","filing":"0001104659-21-123186","document":"tm2129205-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465921123186/tm2129205-2_4seq1.xml","form_type":"4"}},{"id":2561421,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":129140,"kind":"person","name":"Abrahmsen Lars B.","position":1,"cik":"0001789039","reported_name":"Abrahmsen Lars B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2021-09-22T21:00:53.000Z","date":"2021-09-20","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on September 14, 2016 and is fully exercisable."}],"balance_after":80587,"derivative":{"exercise_price":0.92,"expiration_date":"2026-09-14","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-21-118360","document":"tm2127534-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465921118360/tm2127534-3_4seq1.xml","form_type":"4"}},{"id":2561420,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":129140,"kind":"person","name":"Abrahmsen Lars B.","position":1,"cik":"0001789039","reported_name":"Abrahmsen Lars B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-09-22T21:00:53.000Z","date":"2021-09-20","kind":"sale","acquired":false,"shares":25000,"price":4.97,"value":124250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $5.57 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":19000,"source":{"system":"sec-edgar","filing":"0001104659-21-118360","document":"tm2127534-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465921118360/tm2127534-3_4seq1.xml","form_type":"4"}},{"id":2561419,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":129140,"kind":"person","name":"Abrahmsen Lars B.","position":1,"cik":"0001789039","reported_name":"Abrahmsen Lars B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-09-22T21:00:53.000Z","date":"2021-09-20","kind":"exercise","acquired":true,"shares":25000,"price":0.92,"value":23000.0,"ownership":{"direct":true},"balance_after":44000,"source":{"system":"sec-edgar","filing":"0001104659-21-118360","document":"tm2127534-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465921118360/tm2127534-3_4seq1.xml","form_type":"4"}},{"id":2825106,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":129140,"kind":"person","name":"Abrahmsen Lars B.","position":1,"cik":"0001789039","reported_name":"Abrahmsen Lars B.","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2021-03-02T00:08:17.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":82000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":82000,"derivative":{"exercise_price":6,"expiration_date":"2031-02-25","underlying":"Common Stock","underlying_shares":82000},"source":{"system":"sec-edgar","filing":"0001140361-21-006732","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000114036121006732/form4.xml","form_type":"4"}},{"id":2825105,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":129140,"kind":"person","name":"Abrahmsen Lars B.","position":1,"cik":"0001789039","reported_name":"Abrahmsen Lars B.","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-03-02T00:08:17.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 6,333 shares on February 25, 2022, (ii) 6,333 shares on February 25, 2023 and (iii) 6,334 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":19000,"source":{"system":"sec-edgar","filing":"0001140361-21-006732","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000114036121006732/form4.xml","form_type":"4"}},{"id":3193895,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":129140,"kind":"person","name":"Abrahmsen Lars B.","position":1,"cik":"0001789039","reported_name":"Abrahmsen Lars B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2020-03-26T21:01:05.000Z","date":"2020-03-24","kind":"grant","acquired":true,"shares":31600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of these options vest on March 24, 2021, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":31600,"derivative":{"exercise_price":35.5,"expiration_date":"2030-03-24","underlying":"Common Stock","underlying_shares":31600},"source":{"system":"sec-edgar","filing":"0001104659-20-038879","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465920038879/a4.xml","form_type":"4"}},{"id":3396397,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":129140,"kind":"person","name":"Abrahmsen Lars B.","position":1,"cik":"0001789039","reported_name":"Abrahmsen Lars B.","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2019-10-07T23:19:37.000Z","date":"2019-10-07","kind":"grant","acquired":true,"shares":77630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of these options vest on October 2, 2020, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":77630,"derivative":{"exercise_price":15,"expiration_date":"2029-10-02","underlying":"Common Stock","underlying_shares":77630},"source":{"system":"sec-edgar","filing":"0001140361-19-018075","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000114036119018075/form4.xml","form_type":"4"}}]}